Piroxicam and paracetamol in the prevention of early recurrent pain and emergency department readmission after renal colic: Randomized placebo-controlled trial.
nonsteroidal anti‐inflammatory drugs
paracetamol
readmission
recurrent pain
renal colic
Journal
Academic emergency medicine : official journal of the Society for Academic Emergency Medicine
ISSN: 1553-2712
Titre abrégé: Acad Emerg Med
Pays: United States
ID NLM: 9418450
Informations de publication
Date de publication:
19 Aug 2024
19 Aug 2024
Historique:
revised:
09
07
2024
received:
10
04
2024
accepted:
24
07
2024
medline:
20
8
2024
pubmed:
20
8
2024
entrez:
20
8
2024
Statut:
aheadofprint
Résumé
Renal colic (RC) is a common urologic emergency often leading to significant pain and recurrent hospital visits. This study aimed to compare the efficacy and safety of piroxicam versus paracetamol in preventing pain recurrence and hospital readmission in patients treated for RC and discharged from the emergency department (ED). A prospective, randomized, single-blind trial was conducted in four EDs. Eligible adults with RC were randomized to receive oral piroxicam, paracetamol, or placebo for 5 days post-ED discharge. Primary outcomes included pain recurrence and ED readmission within 7 days. Secondary outcomes included time to recurrence and treatment-related side effects. Of 1383 enrolled patients, no significant differences were observed among the groups regarding baseline characteristics. Pain recurrence rates within 7 days were 29% (95% confidence interval [CI] 24.9%-33.2%) for piroxicam, 30.3% (95% CI 26.1%-34.5%) for paracetamol, and 30.8% (95% CI 26.6%-35.0%) for placebo, with no significant between-group differences (p = 0.84). Among patients experiencing recurrence, the majority encounter it within the initial 2 days following their discharge (86% in the piroxicam group, 84.1% in the paracetamol group, and 86% in the placebo group, respectively). ED readmission rates were similar across groups: 20.8% (95% CI 17.1%-24.5%) in the piroxicam group, 23.8% (95% CI 19.9%-27.7%) in the paracetamol group, and 22.9% (95% CI 19.1%-26.8%) in the placebo group (p = 0.52). The piroxicam group reported significantly higher adverse effects compared to others. Piroxicam and paracetamol did not demonstrate efficacy in preventing pain recurrence or ED readmission within the first week following RC treatment.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 The Author(s). Academic Emergency Medicine published by Wiley Periodicals LLC on behalf of Society for Academic Emergency Medicine.
Références
Schoenfeld EM, Pekow PS, Shieh MS, Scales CD, Lagu T, Lindenauer PK. The diagnosis and management of patients with renal colic across a sample of US hospitals: high CT utilization despite low rates of admission and inpatient urologic intervention. PLoS One. 2017;12(1):e0169160.
Wang K, Ge J, Han W, et al. Risk factors for kidney stone disease recurrence: a comprehensive meta‐analysis. BMC Urol. 2022;22(1):62.
Scales CD Jr, Smith AC, Hanley JM, et al. Urologic diseases in America project prevalence of kidney stones in the United States. Eur Urol. 2012;62(1):160‐165.
Scales CD Jr, Lin L, Saigal CS, et al. Emergency department revisits for patients with kidney stones in California. Acad Emerg Med. 2015;22(4):468‐474.
Veser J, Jahrreiss V, Seitz C. Innovations in urolithiasis management. Curr Opin Urol. 2021;31(2):130‐134.
Innes G, McRae A, Grafstein E, et al. Variability of renal colic management and outcomes in two Canadian cities. CJEM. 2018;20(5):702‐712.
Wang Z, Zhang Y, Wei W. Effect of dietary treatment and fluid intake on the prevention of recurrent calcium stones and changes in urine composition: a meta‐analysis and systematic review. PLoS One. 2021;16(4):e0250257.
National Guideline Centre (UK). Dietary Interventions: Renal and Ureteric Stones: Assessment and Management: Intervention Evidence Review (C). National Institute for Health and Care Excellence (NICE); 2019 (NICE Guideline, No. 118).
Frassetto L, Kohlstadt I. Treatment and prevention of kidney stones: an update. Am Fam Physician. 2011;84(11):1234‐1242.
Qaseem A, Dallas P, Forciea MA, Starkey M, Denberg TD, Clinical Guidelines Committee of the American College of Physicians. Dietary and pharmacologic management to prevent recurrent nephrolithiasis in adults: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2014;161(9):659‐667.
Zhong J, Huang Z, Yang T, et al. The current status of preventive measures for urinary calculi in children. Ther Adv Urol. 2021;13:17562872211039581.
Pearle MS, Goldfarb DS, Assimos DG, et al. Medical management of kidney stones: AUA guideline. J Urol. 2014;192(2):316‐324. doi:10.1016/j.juro.2014.05.006
Grenabo L, Holmlund D. Indomethacin as prophylaxis against recurrent ureteral colic. Scand J Urol Nephrol. 1984;18(4):325‐327.
Kapoor DA, Weitzel S, Mowad JJ, Melanson S, Gillen J. Use of indomethacin suppositories in the prophylaxis of recurrent ureteral colic. J Urol. 1989;142(6):1428‐1430.
Laerum E, Ommundsen OE, Grønseth JE, Christiansen A, Fagertun HE. Oral diclofenac in the prophylactic treatment of recurrent renal colic. A double‐blind comparison with placebo. Eur Urol. 1995;28(2):108‐111.
Degheili JA, Abou Heidar N, Yacoubian A, Moussawy M, Bachir BG. Epidemiology and composition of nephrolithiasis in a Lebanese tertiary care center: a descriptive study. Urol Ann. 2022;14(3):222‐226. doi:10.4103/ua.ua_117_21
González‐Enguita C, Bueno‐Serrano G, López de Alda‐González A, García‐Giménez R. Environmental conditions as determinants of kidney stone formation. ACS Appl Bio Mater. 2023;6(11):5030‐5036.
Pathan SA, Mitra B, Cameron PA. A systematic review and meta‐analysis comparing the efficacy of nonsteroidal anti‐inflammatory drugs, opioids, and paracetamol in the treatment of acute renal colic. Eur Urol. 2018;73(4):583‐595.
Nakada SY, Jerde TJ, Bjorling DE, et al. Selective cyclooxygenase‐2 inhibitors reduce ureteral contraction in vitro: a better alternative for renal colic? J Urol. 2000;163(2):607‐612.
Supervía A, Pedro‐Botet J, Nogués X, et al. Piroxicam fast‐dissolving dosage form vs diclofenac sodium in the treatment of acute renal colic: a double‐blind controlled trial. Br J Urol. 1998;81(1):27‐30.
Al‐Waili NS, Saloom KY. Intramuscular piroxicam versus intramuscular diclofenac sodium in the treatment of acute renal colic: double‐blind study. Eur J Med Res. 1999;4(1):23‐26.
Al B, Sunar MM, Zengin S, et al. Comparison of IV dexketoprofen trometamol, fentanyl, and paracetamol in the treatment of renal colic in the ED: a randomized controlled trial. Am J Emerg Med. 2018;36(4):571‐576.
Grissa MH, Claessens YE, Bouida W, et al. Paracetamol vs piroxicam to relieve pain in renal colic. Results of a randomized controlled trial. Am J Emerg Med. 2011;29(2):203‐206.